RecruitingNCT07421739

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Sponsor

Aura Biosciences

Enrollment

15 participants

Start Date

Nov 12, 2025

Study Type

OBSERVATIONAL

Conditions

Uveal Melanoma Choroidal Melanoma Indeterminate Lesions Ocular Melanoma

Summary

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study collects patient-reported outcomes — how patients themselves feel about their quality of life, vision, and emotional health — from a subset of participants already enrolled in the CoMpass trial (AU-011-301), which is testing a treatment for choroidal melanoma, a type of eye cancer. **You may be eligible if...** - You are already enrolled in the AU-011-301 (CoMpass) clinical trial - You have access to a smartphone, laptop, or tablet **You may NOT be eligible if...** - You are not enrolled in the CoMpass trial - There are no other exclusion criteria listed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-interventional, digital, patient-reported, real-world study

Surveys will be collected at the following key timepoints: Scheduled visits: Visit 2\_Cycle 1\_Day 1 Visit 8 (week 4, Day 29) Visit 19 (24-hr f/y +/- 4hrs last tx) Visit 20 (week 12, day 84) Visit 22 (week 20, day 84) Visit 25 (week 52, day 364) Visit 26 (week 65, day 455) Visit 27 (week 78, day 546) Visit 28 (week 91, day 637) Visit 29 (week 104, day 728) End of Trial or Early Termination